ASKA Pharmaceutical Holdings Co., Ltd. (JP:4886)
:4886
Want to see JP:4886 full AI Analyst Report?
4886 Stock Chart & Stats
¥2038.00
-¥23.00(-1.13%)
At close: 4:00 PM EST
¥2038.00
-¥23.00(-1.13%)
Day’s Range― - ―
52-Week Range¥1,920.00 - ¥3,020.00
Previous CloseN/A
Volume48.10K
Average Volume (3M)49.10K
Market Cap
¥79.62B
Enterprise Value¥92.99B
Total Cash (Recent Filing)¥7.23B
Total Debt (Recent Filing)¥13.77B
Price to Earnings (P/E)8.6
Beta0.55
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.52%
Share Statistics
EPS (TTM)59.10
Shares Outstanding28,763,199
10 Day Avg. Volume37,820
30 Day Avg. Volume49,100
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)1.00
Price to Sales (P/S)1.02
P/FCF Ratio-137.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)197.8
Revenue Forecast (FY)¥71.06B
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthSustained top-line expansion provides a durable foundation for investment in R&D and lifecycle management of branded drugs. Multi-year revenue growth supports predictable demand in core therapeutic areas and underpins longer-term margin and cash generation potential.
High Gross MarginsHealthy gross margins indicate structural pricing power or low variable costs in its specialty prescription portfolio. That margin headroom helps absorb R&D and SG&A, improving the firm's ability to sustain profitability through product cycles and to reinvest in the pipeline.
Stronger Balance SheetMarked deleveraging and a high equity ratio enhance financial flexibility, lowering refinancing risk and enabling capital allocation for strategic R&D, M&A or dividends. A stronger balance sheet increases resilience to industry cycles and supports long-term execution.
Bears Say
Falling Net Profit MarginsA material drop in net margins reduces the company’s long-term earnings power and free cash available for reinvestment. If persistent, lower margins constrain the ability to fund pipeline development and could pressure strategic flexibility amid competitive or cost headwinds.
Inconsistent Free Cash FlowVolatile and declining free cash flow undermines sustainable funding for R&D, dividends and debt reduction. Even with positive operating cash to net income, weaker FCF increases reliance on balance sheet buffers and raises execution risk for long-term projects.
Negative EPS TrendA negative EPS trend signals pressure on reported earnings that may reflect margin compression or one-off costs. Persistent EPS declines can erode investor confidence and limit internally generated capital for sustained product development and growth initiatives.
ASKA Pharmaceutical Holdings Co., Ltd. News
4886 FAQ
What was ASKA Pharmaceutical Holdings Co., Ltd.’s price range in the past 12 months?
ASKA Pharmaceutical Holdings Co., Ltd. lowest stock price was ¥1920.00 and its highest was ¥3020.00 in the past 12 months.
What is ASKA Pharmaceutical Holdings Co., Ltd.’s market cap?
ASKA Pharmaceutical Holdings Co., Ltd.’s market cap is ¥79.62B.
When is ASKA Pharmaceutical Holdings Co., Ltd.’s upcoming earnings report date?
ASKA Pharmaceutical Holdings Co., Ltd.’s upcoming earnings report date is May 07, 2026 which is in 11 days.
How were ASKA Pharmaceutical Holdings Co., Ltd.’s earnings last quarter?
ASKA Pharmaceutical Holdings Co., Ltd. released its earnings results on Feb 02, 2026. The company reported ¥59.1 earnings per share for the quarter, beating the consensus estimate of N/A by ¥59.1.
Is ASKA Pharmaceutical Holdings Co., Ltd. overvalued?
According to Wall Street analysts ASKA Pharmaceutical Holdings Co., Ltd.’s price is currently Overvalued.
Does ASKA Pharmaceutical Holdings Co., Ltd. pay dividends?
ASKA Pharmaceutical Holdings Co., Ltd. pays a Semiannually dividend of ¥28 which represents an annual dividend yield of 2.52%. See more information on ASKA Pharmaceutical Holdings Co., Ltd. dividends here
What is ASKA Pharmaceutical Holdings Co., Ltd.’s EPS estimate?
ASKA Pharmaceutical Holdings Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ASKA Pharmaceutical Holdings Co., Ltd. have?
ASKA Pharmaceutical Holdings Co., Ltd. has 28,763,199 shares outstanding.
What happened to ASKA Pharmaceutical Holdings Co., Ltd.’s price movement after its last earnings report?
ASKA Pharmaceutical Holdings Co., Ltd. reported an EPS of ¥59.1 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -7.046%.
Which hedge fund is a major shareholder of ASKA Pharmaceutical Holdings Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4886
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ASKA Pharmaceutical Holdings Co., Ltd.
ASKA Pharmaceutical Holdings Co.,Ltd., through its subsidiaries, engages in the pharmaceutical, animal health, and hormone testing businesses in Japan. The company researches, develops, manufactures, and markets pharmaceutical products in the areas of endocrinology, obstetrics and gynecology, and urology; and manufactures, sells, imports, and exports veterinary medicines, veterinary medical devices, feed and feed additives, reagents, agrochemicals, industrial chemicals, hygiene products, and food products and their raw materials. It is also involved in the clinical examination and biological testing activities; and offers medical devices. The company was founded in 1920 and is headquartered in Tokyo, Japan.
Technical Analysis
Kaken Pharmaceutical Co
―
Fuji Pharma Co., Ltd.
―
Mochida Pharmaceutical Co., Ltd.
―
KYORIN Pharmaceutical Co.,Ltd.
―
Daito Pharmaceutical Co., Ltd.
―
Options Prices
Currently, No data available
---